GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CytoSorbents Corp (NAS:CTSO) » Definitions » PB Ratio

CytoSorbents (CytoSorbents) PB Ratio : 2.05 (As of May. 05, 2024)


View and export this data going back to 2005. Start your Free Trial

What is CytoSorbents PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-05), CytoSorbents's share price is $0.88. CytoSorbents's Book Value per Share for the quarter that ended in Dec. 2023 was $0.43. Hence, CytoSorbents's PB Ratio of today is 2.05.

The historical rank and industry rank for CytoSorbents's PB Ratio or its related term are showing as below:

CTSO' s PB Ratio Range Over the Past 10 Years
Min: 1.27   Med: 14.45   Max: 118.52
Current: 2.05

During the past 13 years, CytoSorbents's highest PB Ratio was 118.52. The lowest was 1.27. And the median was 14.45.

CTSO's PB Ratio is ranked better than
53.41% of 792 companies
in the Medical Devices & Instruments industry
Industry Median: 2.245 vs CTSO: 2.05

During the past 12 months, CytoSorbents's average Book Value Per Share Growth Rate was -47.10% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -38.40% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 14.70% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of CytoSorbents was 97.70% per year. The lowest was -142.10% per year. And the median was 22.30% per year.

Back to Basics: PB Ratio


CytoSorbents PB Ratio Historical Data

The historical data trend for CytoSorbents's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoSorbents PB Ratio Chart

CytoSorbents Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.67 4.35 2.91 1.91 2.59

CytoSorbents Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.91 5.11 6.59 4.51 2.59

Competitive Comparison of CytoSorbents's PB Ratio

For the Medical Devices subindustry, CytoSorbents's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytoSorbents's PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CytoSorbents's PB Ratio distribution charts can be found below:

* The bar in red indicates where CytoSorbents's PB Ratio falls into.



CytoSorbents PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

CytoSorbents's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=0.88/0.429
=2.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


CytoSorbents  (NAS:CTSO) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


CytoSorbents PB Ratio Related Terms

Thank you for viewing the detailed overview of CytoSorbents's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CytoSorbents (CytoSorbents) Business Description

Traded in Other Exchanges
Address
305 College Road East, Princeton, NJ, USA, 08540
CytoSorbents Corp is involves in the treatment of life-threatening conditions in the intensive care (ICU) and cardiac surgery using blood purification via proprietary polymer adsorption technology. It has a number of products commercialized and in development based on this technology platform.
Executives
Edward Raymond Jones director 70 HOGAN LANE, AMBLER PA 19002
Kathleen P. Bloch officer: Chief Financial Officer 3 PERSHING COURT, NORTH BRUNSWICK NJ 08902
Vincent Capponi officer: Chief Operating Officer MEDASORB TECHNOLOGIES, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Phillip P. Chan director, officer: President and CEO 1001 BRIGGS ROAD, SUITE 280, MOUNT LAUREL NJ 08054
Efthymios Deliargyris officer: Chief Medical Officer C/O PLX PHARMA,INC.8285 EL RIO STREET, SUITE 210, HOUSTON TX 77054
Jiny Kim director C/O CYTOSORBENTS CORPORATION, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Alan D. Sobel director 293 EISENHOWER PARKWAY, LIVINGSTON NJ 07039
Michael G. Bator director C/O CYTOSORBENTS CORP., 7 DEER PARK DR., SUITE K, MONMOUTH JUNCTION NJ 08852
Alex D'amico officer: Chief Financial Officer 10 EAST PASSAIC AVENUE, UNIT C-2, NUTLEY NJ 07110
Al Kraus director MEDASORB TECHNOLOGIES, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Eric R. Mortensen officer: Chief Medical Officer C/O CYTOSORBENTS CORPORATION, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Njtc Investment Fund, Lp 10 percent owner 1001 BRIGGS ROAD, SUITE 280, MOUNT LAUREL NJ 08054
Robert Shipley 10 percent owner 9 NOBLE ROAD, NOGALES AZ 85621
Ronald Berger officer: See Remarks 7 DEERPARK DRIVE, STE K, MONMOUTH JUNCTION NJ 08852
Thomas Bocchino officer: Chief Financial Officer C/O CYTOSORBENTS CORP., 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852